SE514128C2 - Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit - Google Patents

Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit

Info

Publication number: SE514128C2
Authority: SE; Sweden
Prior art keywords: use according; medicament; glucocorticoid; treatment; glomerulonephritis
Prior art date: 1998-03-17

Application number

SE9800905A

Other languages

English (en)

Swedish (sv)

Other versions

SE9800905L (sv

SE9800905D0 (sv

Inventor

Roger Haellgren

Bengt Fellstroem

Original Assignee

Pharmalink Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-17

Filing date

1998-03-17

Publication date

2001-01-08

1998-03-17 Application filed by Pharmalink Ab filed Critical Pharmalink Ab

1998-03-17 Priority to SE9800905A priority Critical patent/SE514128C2/sv

1998-03-17 Publication of SE9800905D0 publication Critical patent/SE9800905D0/xx

1999-03-11 Priority to US09/266,023 priority patent/US6239120B1/en

1999-03-16 Priority to BR9908838-0A priority patent/BR9908838A/pt

1999-03-16 Priority to EP99910932A priority patent/EP1056461B1/de

1999-03-16 Priority to CNB998041351A priority patent/CN1152688C/zh

1999-03-16 Priority to PCT/SE1999/000406 priority patent/WO1999047144A1/en

1999-03-16 Priority to KR1020007009283A priority patent/KR20010041204A/ko

1999-03-16 Priority to JP2000536384A priority patent/JP4326696B2/ja

1999-03-16 Priority to AU29686/99A priority patent/AU749199B2/en

1999-03-16 Priority to CA002317796A priority patent/CA2317796A1/en

1999-03-16 Priority to ES99910932T priority patent/ES2181407T3/es

1999-03-16 Priority to AT99910932T priority patent/ATE224195T1/de

1999-03-16 Priority to DE69902999T priority patent/DE69902999T2/de

1999-09-18 Publication of SE9800905L publication Critical patent/SE9800905L/

2001-01-08 Publication of SE514128C2 publication Critical patent/SE514128C2/sv

Links

238000011282 treatment Methods 0.000 title claims abstract description 36
239000003862 glucocorticoid Substances 0.000 title claims abstract description 30
206010018364 Glomerulonephritis Diseases 0.000 title claims abstract description 17
239000003814 drug Substances 0.000 title claims abstract description 10
238000004519 manufacturing process Methods 0.000 title claims abstract description 5
210000003734 kidney Anatomy 0.000 claims abstract description 18
238000010579 first pass effect Methods 0.000 claims abstract description 3
210000004185 liver Anatomy 0.000 claims abstract 2
208000010159 IgA glomerulonephritis Diseases 0.000 claims description 18
206010021263 IgA nephropathy Diseases 0.000 claims description 18
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 13
229960004436 budesonide Drugs 0.000 claims description 12
230000009885 systemic effect Effects 0.000 claims description 9
239000003826 tablet Substances 0.000 claims description 8
239000002775 capsule Substances 0.000 claims description 5
210000000813 small intestine Anatomy 0.000 claims description 4
241000792859 Enema Species 0.000 claims description 3
239000007920 enema Substances 0.000 claims description 3
239000008187 granular material Substances 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 3
239000006188 syrup Substances 0.000 claims description 3
235000020357 syrup Nutrition 0.000 claims description 3
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
229950000210 beclometasone dipropionate Drugs 0.000 claims description 2
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 2
229940092705 beclomethasone Drugs 0.000 claims description 2
229940079360 enema for constipation Drugs 0.000 claims description 2
239000002702 enteric coating Substances 0.000 claims description 2
238000009505 enteric coating Methods 0.000 claims description 2
239000006260 foam Substances 0.000 claims description 2
239000006187 pill Substances 0.000 claims description 2
239000000843 powder Substances 0.000 claims description 2
239000000829 suppository Substances 0.000 claims description 2
230000000968 intestinal effect Effects 0.000 claims 1
239000003094 microcapsule Substances 0.000 claims 1
-1 ro 'eponide Chemical compound 0.000 claims 1
239000000243 solution Substances 0.000 claims 1
229960002117 triamcinolone acetonide Drugs 0.000 claims 1
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 7
210000000936 intestine Anatomy 0.000 abstract description 6
239000002671 adjuvant Substances 0.000 abstract description 4
238000000034 method Methods 0.000 abstract description 4
239000003085 diluting agent Substances 0.000 abstract description 3
239000003937 drug carrier Substances 0.000 abstract description 2
239000013543 active substance Substances 0.000 abstract 3
239000000126 substance Substances 0.000 description 19
201000001474 proteinuria Diseases 0.000 description 13
230000000694 effects Effects 0.000 description 8
238000011862 kidney biopsy Methods 0.000 description 8
230000003907 kidney function Effects 0.000 description 7
238000010562 histological examination Methods 0.000 description 6
239000000463 material Substances 0.000 description 6
229940109239 creatinine Drugs 0.000 description 5
229940037128 systemic glucocorticoids Drugs 0.000 description 5
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
208000037157 Azotemia Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000002784 sclerotic effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
208000009852 uremia Diseases 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000294754 Macroptilium atropurpureum Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000002220 antihypertensive agent Substances 0.000 description 2
229940127088 antihypertensive drug Drugs 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
229960003624 creatine Drugs 0.000 description 2
239000006046 creatine Substances 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
229940124589 immunosuppressive drug Drugs 0.000 description 2
230000001788 irregular Effects 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000002429 large intestine Anatomy 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
201000001119 neuropathy Diseases 0.000 description 2
230000007823 neuropathy Effects 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
201000008171 proliferative glomerulonephritis Diseases 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
210000005239 tubule Anatomy 0.000 description 2
239000005541 ACE inhibitor Substances 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
229920000945 Amylopectin Polymers 0.000 description 1
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
206010018366 Glomerulonephritis acute Diseases 0.000 description 1
206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010066453 Mesangioproliferative glomerulonephritis Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960003728 ciclesonide Drugs 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 1
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Natural products CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 1
229940079920 digestives acid preparations Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000000975 dye Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
229940002671 entocort Drugs 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
201000008350 membranous glomerulonephritis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000885 nephron Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
229940096976 rectal foam Drugs 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
230000013878 renal filtration Effects 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000002676 xenobiotic agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

SE9800905A 1998-03-17 1998-03-17 Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit SE514128C2 (sv)

Priority Applications (13)

Application Number	Priority Date	Filing Date	Title
SE9800905A SE514128C2 (sv)	1998-03-17	1998-03-17	Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit
US09/266,023 US6239120B1 (en)	1998-03-17	1999-03-11	Method and means for treating glomerulonephritis
DE69902999T DE69902999T2 (de)	1998-03-17	1999-03-16	Glucocorticoide zur behandlung von glomerulonephitis
KR1020007009283A KR20010041204A (ko)	1998-03-17	1999-03-16	사구체신염의 치료 방법 및 수단
EP99910932A EP1056461B1 (de)	1998-03-17	1999-03-16	Glucocorticoide zur behandlung von glomerulonephitis
CNB998041351A CN1152688C (zh)	1998-03-17	1999-03-16	糖皮质激素用于制备治疗肾小球肾炎的药剂的用途及该药剂用于治疗IgA 肾病的用途
PCT/SE1999/000406 WO1999047144A1 (en)	1998-03-17	1999-03-16	Method and means for treating glomerulonephritis
BR9908838-0A BR9908838A (pt)	1998-03-17	1999-03-16	Uso de um glicocorticóide, processeo para tratar glomerulonefrite aguda ou crÈnica, e, composição farmacêutica para tratar glomerulonefrite
JP2000536384A JP4326696B2 (ja)	1998-03-17	1999-03-16	糸球体腎炎の治療のための方法および手段
AU29686/99A AU749199B2 (en)	1998-03-17	1999-03-16	Method and means for treating glomerulonephritis
CA002317796A CA2317796A1 (en)	1998-03-17	1999-03-16	Method and means for treating glomerulonephritis
ES99910932T ES2181407T3 (es)	1998-03-17	1999-03-16	Glucocorticoides para tratar la glomerulonefritis.
AT99910932T ATE224195T1 (de)	1998-03-17	1999-03-16	Glucocorticoide zur behandlung von glomerulonephitis

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9800905A SE514128C2 (sv)	1998-03-17	1998-03-17	Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit

Publications (3)

Publication Number	Publication Date
SE9800905D0 SE9800905D0 (sv)	1998-03-17
SE9800905L SE9800905L (sv)	1999-09-18
SE514128C2 true SE514128C2 (sv)	2001-01-08

Family

ID=20410600

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9800905A SE514128C2 (sv)	1998-03-17	1998-03-17	Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit

Country Status (12)

Country	Link
EP (1)	EP1056461B1 (de)
JP (1)	JP4326696B2 (de)
KR (1)	KR20010041204A (de)
CN (1)	CN1152688C (de)
AT (1)	ATE224195T1 (de)
AU (1)	AU749199B2 (de)
BR (1)	BR9908838A (de)
CA (1)	CA2317796A1 (de)
DE (1)	DE69902999T2 (de)
ES (1)	ES2181407T3 (de)
SE (1)	SE514128C2 (de)
WO (1)	WO1999047144A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR026073A1 (es) *	1999-10-20	2002-12-26	Nycomed Gmbh	Composicion farmaceutica acuosa que contiene ciclesonida
AR026072A1 (es) *	1999-10-20	2002-12-26	Nycomed Gmbh	Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa
AU2004271743B2 (en) *	2003-09-15	2010-06-10	Covis Pharma B.V.	Use of ciclesonide for the treatment of inflammatory bowel diseases
GB0808537D0 (en) *	2008-05-12	2008-06-18	Archimedes Dev Ltd	Compositions
EP3760187A1 (de)	2009-10-01	2021-01-06	Adare Pharmaceuticals US, L.P.	Oral verabreichte corticosteroidzusammensetzungen
WO2015034678A2 (en)	2013-09-06	2015-03-12	Aptalis Pharmatech, Inc.	Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
JP7376582B2 (ja) *	2018-10-22	2023-11-08	イーオーイーオレオゲーエムベーハー	成形体への圧縮を目的とした粉末材料用添加剤
US11896719B2 (en)	2022-01-24	2024-02-13	Calliditas Therapeutics Ab	Pharmaceutical compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5643602A (en) *	1989-11-22	1997-07-01	Astra Aktiebolag	Oral composition for the treatment of inflammatory bowel disease

1998
- 1998-03-17 SE SE9800905A patent/SE514128C2/sv not_active IP Right Cessation
1999
- 1999-03-16 WO PCT/SE1999/000406 patent/WO1999047144A1/en not_active Ceased
- 1999-03-16 DE DE69902999T patent/DE69902999T2/de not_active Expired - Lifetime
- 1999-03-16 CA CA002317796A patent/CA2317796A1/en not_active Abandoned
- 1999-03-16 ES ES99910932T patent/ES2181407T3/es not_active Expired - Lifetime
- 1999-03-16 EP EP99910932A patent/EP1056461B1/de not_active Expired - Lifetime
- 1999-03-16 JP JP2000536384A patent/JP4326696B2/ja not_active Expired - Lifetime
- 1999-03-16 BR BR9908838-0A patent/BR9908838A/pt not_active IP Right Cessation
- 1999-03-16 AU AU29686/99A patent/AU749199B2/en not_active Expired
- 1999-03-16 KR KR1020007009283A patent/KR20010041204A/ko not_active Withdrawn
- 1999-03-16 AT AT99910932T patent/ATE224195T1/de not_active IP Right Cessation
- 1999-03-16 CN CNB998041351A patent/CN1152688C/zh not_active Expired - Lifetime

Also Published As

Publication number	Publication date
SE9800905L (sv)	1999-09-18
CN1152688C (zh)	2004-06-09
DE69902999D1 (de)	2002-10-24
EP1056461A1 (de)	2000-12-06
AU2968699A (en)	1999-10-11
JP4326696B2 (ja)	2009-09-09
WO1999047144A1 (en)	1999-09-23
SE9800905D0 (sv)	1998-03-17
JP2002506824A (ja)	2002-03-05
CA2317796A1 (en)	1999-09-23
ATE224195T1 (de)	2002-10-15
DE69902999T2 (de)	2003-06-05
AU749199B2 (en)	2002-06-20
CN1293572A (zh)	2001-05-02
BR9908838A (pt)	2000-12-12
EP1056461B1 (de)	2002-09-18
KR20010041204A (ko)	2001-05-15
ES2181407T3 (es)	2003-02-16

Legal Events

Date	Code	Title	Description
2018-05-02	NUG	Patent has lapsed

Publication	Publication Date	Title
Fedorak et al.	2005	Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide
US20070149465A1 (en)	2007-06-28	Compositions and methods for prevention and treatment of cachexia
EP3897589B1 (de)	2025-12-03	Pharmazeutische formulierungen mit relacorilant, einer heteroaryl-keton kondensierten azadecalin-verbindung
EP0502092A1 (de)	1992-09-09	Orale zusammensetzung für die behandlung intestinaler entzündlicher krankheiten.
SK284539B6 (sk)	2005-06-02	Použitie nikotínu, farmaceutické kompozície a farmaceutický kombinačný produkt
KR102537990B1 (ko)	2023-05-30	스테로이드 용량의 감소 및 염증과 자가면역 질환의 치료를 위한 칸나비디올
JP2005508346A (ja)	2005-03-31	免疫炎症疾患の治療のための組合せ
WO1997034605A1 (en)	1997-09-25	Use of nicotine to treat liver disease
SE514128C2 (sv)	2001-01-08	Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit
US6239120B1 (en)	2001-05-29	Method and means for treating glomerulonephritis
TW201247612A (en)	2012-12-01	Compositions for treating kidney disorders
US20100184732A1 (en)	2010-07-22	Method of long-term treatment of graft-versus-host disease using topical active corticosteroids
US20080262071A1 (en)	2008-10-23	Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder
MXPA00008173A (en)	2002-03-05	Method and means for treating glomerulonephritis
KR20250102046A (ko)	2025-07-04	다주코릴란트를 이용한 근위축성 측삭경화증의 치료
US20040006053A1 (en)	2004-01-08	Method of long-term treatment of Graft-Versus-Host Disease using topical active corticosteriods
WO2024249509A1 (en)	2024-12-05	Sparsentan for use in a method of treating iga-mediated diseases
EP1793818A2 (de)	2007-06-13	Pindolol zur behandlung des prämenstruellen syndroms und von prämenstrueller dysphorie
Burggraaf et al.	1998	The gastrointestinal passage and release of beclomethasone dipropionate from oral delivery systems in ileostomy volunteers
CA2413883C (en)	2009-07-28	Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation
HK40067500A (en)	2022-09-09	Natural combination hormone replacement formulations and therapies
CN110062634A (zh)	2019-07-26	非酒精性脂肪肝病患者中纤维化的抑制
US20140328929A1 (en)	2014-11-06	Method of Preventing Acute Graft-Versus-Host Disease using Oral Beclomethasone Dipropionate
ZA200205234B (en)	2003-09-29	Use of rofleponide in the treatment of irritable bowel syndrome (IBS).
WO2001003703A1 (en)	2001-01-18	An oral composition having as a first active ingredient rofleponide and as a second active ingredient an antibiotic, for use in intestinal conditions, especially crohn's disease